Latest News

8 December 2016

Higher BMI in Adolescence May Affect Cognitive Function in Midlife

Hebrew University of Jerusalem

Overweight and obesity in adolescents have increased substantially in recent decades, and today affect a third of the adolescent population in some developed countries. While the dangers posed by high adult BMI on cognitive function in later life have been documented, the association of adolescent BMI with cognitive function in midlife has not yet been reported.

27 November 2016

New Study Shows Marijuana Users have Low Blood Flow to the Brain

Brain image of healthy person versus daily user of marijuana

As the U.S. races to legalize marijuana for medicinal and recreational use, a new, large scale brain imaging study gives reason for caution. Published in the Journal of Alzheimer’s Disease, researchers using single photon emission computed tomography (SPECT), a sophisticated imaging study that evaluates blood flow and activity patterns, demonstrated abnormally low blood flow in virtually every area of the brain studies in nearly 1,000 marijuana compared to healthy controls, including areas known to be affected by Alzheimer’s pathology such as the hippocampus.

23 November 2016

UTMB study offers new insight into how Alzheimer’s disease begins

UTMB Health Media Relations

A new study from The University of Texas Medical Branch at Galveston offers important insight into how Alzheimer’s disease begins within the brain. The researchers found a relationship between inflammation, a toxic protein and the onset of the disease. The study also identified a way that doctors can detect early signs of Alzheimer’s by looking at the back of patients’ eyes.

20 November 2016

Aurin Biotech's Simple Saliva Test Predicts Future Onset of Alzheimer's Disease

Pat McGeer

Aurin Biotech announced today that it has developed a simple saliva test that can diagnose Alzheimer's disease, as well as predict its future onset, allowing individuals to take preventive measures before the disease takes hold. The disease, which affects an estimated 35 million people worldwide, is predicted to double in 20 years if progress is not made. In addition, the current cost of caring for Alzheimer's patients is estimated at more than $500 billion per year.

1 November 2016

A Novel and Intelligent Home Monitoring System for Care Support of Elders with Cognitive Impairment

Greek researchers demonstrated the potential use of assistive technologies for people with dementia, to fulfill an important need: the improvement of clinical diagnosis and decision making meeting individual needs. Remote home monitoring of patients is a promising “participant-centered” management approach which provides relevant and reliable information that enables clinicians to drive adaptive interventions.

22 September 2016

Study Demonstrates Mass Spectrometry Technique Dramatically Enhances Detection of Key Early Stage Alzheimer’s Biomarkers

Proteome Sciences

A peer reviewed study led by Proteome Sciences plc (“Proteome Sciences”), in conjunction with a group of highly respected universities and hospitals, demonstrates the ability of an innovative mass spectrometry workflow to dramatically improve the ability to detect tau-derived peptides that are directly related to human Alzheimer’s pathology as early stage biomarkers of the disease. Published on-line in the Journal of Alzheimer’s Disease, the study describes the application of the workflow, TMTcalibrator, for high-sensitivity detection of phosphorylated tau and other disease-relevant biomarkers of Alzheimer’s disease in cerebrospinal fluid.

14 September 2016

Specific Triazine Herbicides Induce Amyloid-β42 Production

A new study led by Laurent Meijer, at ManRos Therapeutics, and collaborators shows that some herbicides (triazines) trigger enhanced in vitro production of the Aβ42 over Aβ40 amyloid peptides in various cell lines. This suggests that some products from the ‘human chemical exposome’ (HCE) (estimated to be over 85,000 products) may contribute to the increased production of Aβ42 over Aβ40 characteristic of Alzheimer’s disease (AD). In addition, some of these products might be turned into pharmacological tools to develop a chemically-induced animal model of AD (in contrast with the currently used genetic, recombinant mice models).

13 September 2016

Online advice for preventing Alzheimer’s disease often problematic: UBC research

Julie Robillard

New UBC research finds that many online resources for preventing Alzheimer’s disease are problematic and could be steering people in the wrong direction. In a survey of online articles about preventing Alzheimer’s disease, UBC researchers found many websites offered poor advice and one in five promoted products for sale—a clear conflict of interest.

9 September 2016

Efficacy and Safety of Crocus Sativus L in Patients with Mild Cognitive Impairment: One Year Single-Blind Randomized, with Parallel Groups, Clinical Trial

Crocus Sativus

Greek researchers and clinicians demonstrated the potential of Crocus Sativus L. (saffron) as a therapeutic pharmaceutical natural compound for older adults with amnestic Mild Cognitive Impairment (aMCI). MCI is a condition that often predates Alzheimer’s disease (AD) and is characterized by memory loss and inability to execute complex Activities of Daily Living. While there is no treatment for MCI and symptomatic only treatment for AD, the global effort against cognitive disorders is focused on early detection and management of AD at the stage of MCI.


Subscribe to Latest News